Therefore, the pancreatic ductal adenocarcinoma with wild-type KRAS seems to have the most favorable prognosis when accomplished by gHRR mutations, which is probably responsible for the best response to therapy. The gene discussed is KRAS; the disease is pancreatic ductal adenocarcinoma.